Clinical trial
TBP Study With Capecitabine Plus Minus Trastuzumab
NCT00148876 · GBG Forschungs GmbH, Other · Completed
Key facts
| NCT number | NCT00148876 |
|---|---|
| Title | TBP Study With Capecitabine Plus Minus Trastuzumab |
| Official title | A Multicenter Randomized Phase III Study to Compare Capecitabine Alone or in Combination With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer and Progression After Previous Treatment With Trastuzumab |
| Lead sponsor | GBG Forschungs GmbH, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Trastuzumab |
| Enrollment | 482 |
| Start date | Sep 1, 2003 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Sep 8, 2005 |
| Last update posted | Feb 23, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: